RecruitingNCT06947941
KarXT with KarX-EC for psychosis associated with Alzheimer’s disease
About this title
Read the official source — NCT06947941Medication studyAges 55–90Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 90 years.
- Listed locations
- Gilbert and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 25, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 325
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- From 55 Years to 90 Years
- Official registry ID
- NCT06947941
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
Recruitment & locations
RecruitingGilbert, United States · Chino, United States · Naples, United States
17 more locations
- Cleveland, United States
- Independence, United States
- Macquarie Park, Australia
- Nedlands, Australia
- Toronto, Canada
- Whitby, Canada
- Montreal, Canada
- Suita, Japan
- Nankoku-shi, Japan
- Osaka, Japan
- Exeter, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Chertsey, United Kingdom
- Sheffield, United Kingdom
- Crowborough, United Kingdom
- Motherwell, United Kingdom
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including KarXT and KarX-EC.
Who can participate?
Listed age limits: 55 years to 90 years.
Is this study still recruiting?
The registry lists this study as recruiting.
